Strathspey Crown and the first Medicare-Medicaid opt-out company in medtech | A conversation with Robert Grant

December 3, 2012 by Brian Johnson

In this MassDevice Big 100 West preview, we talk to Strathspey Crown Chairman Robert Grant about how his private equity firm Strathspey Crown is looking to break the mold.

Strathspey Crown CEO Robert Grant

If Robert Grant is successful – a good bet, judging by his track record – 1 day his new venture, private equity firm Strathspey Crown, will be known as a leader in the nascent field of "lifestyle medicine."

Grant, a former president of Allergan (NYSE:AGN) and, most recently, CEO of Bausch & Lomb, describes lifestyle medicine as an umbrella of products, floating across aesthetics, dentistry, ophthalmic, sports medicine and other areas of healthcare that are focused on improving life, rather than saving or prolonging it.

More important to the long-term future of healthcare, however, may be Strathspey's ambition to be the first Medicare-Medicaid opt-out manufacturer in medical technology, by acquiring companies and technologies that don't take a single dollar from the government insurance programs – and therefore aren't subject to stifling government regulations Grant blames for weighing down a large swath of the healthcare market.

We caught up with Grant recently, in advance of his appearance as a panelist at the upcoming MassDevice Big 100 Roundtable West, to discuss the inspiration behind Strathspey Crown, his push to return power to physicians and how the U.S. is turning into a 2-tiered healthcare system.

Interested in hearing more in person? Register here to join us Dec. 11 Talk me through the thought process behind the creation of this new entity called Strathspey Crown.

Robert Grant: I saw a compelling need in the marketplace, because companies and doctors, due to over-regulation, are no longer able to work closely together anymore. I felt that, at its core, this was very problematic, because during the course of my career the relationship between physicians and companies has led to the American engine of innovation in medicine. It's always the doctors that come up with the ideas.



Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells

David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years. brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.